Childress James F
Institute for Practical Ethics and Public Life, University of Virginia, Charlottesville, VA 22904-4126, USA.
Fetal Diagn Ther. 2004 Mar-Apr;19(2):119-23. doi: 10.1159/000075133.
The bioethical controversy about public policy in the United States regarding human stem cell research, particularly with regard to several potential sources of stem cells, including aborted fetuses, unimplanted embryos following in vitro fertilization (IVF), and embryos created through IVF or cloning for research purposes is examined. On the one hand, the debate about the use of federal funds for this research was not resolved by President Bush's policy, announced in August 2001, because only a few cell lines are available under this restrictive policy. On the other hand, debate persists about whether the US should adopt a prohibitive, regulatory, or permissive policy toward the deliberate creation of embryos for biomedical research through somatic cell nuclear transfer. Although there is a wide consensus about the need to ban cloning-for-reproduction, there is deep division, reflected in the work of the President's Council on Bioethics, about a possible ban on cloning-for-biomedical research. The author concludes that ethical controversy will probably persist about both types of policy, and that the policy stalemate will probably also continue, because of fundamental disagreements about the moral status of the early embryo.
本文探讨了美国关于人类干细胞研究公共政策的生物伦理争议,特别是涉及几种潜在的干细胞来源,包括堕胎胎儿、体外受精(IVF)后未植入的胚胎,以及为研究目的通过IVF或克隆产生的胚胎。一方面,关于使用联邦资金进行此项研究的辩论并未因布什总统2001年8月宣布的政策而得到解决,因为在这一限制性政策下仅有少数细胞系可用。另一方面,对于美国是否应针对通过体细胞核移植故意制造用于生物医学研究的胚胎采取禁止、监管或许可政策的辩论仍在继续。尽管对于禁止生殖性克隆的必要性存在广泛共识,但在总统生物伦理委员会的工作中反映出,对于是否可能禁止生物医学研究性克隆存在严重分歧。作者得出结论,由于对于早期胚胎道德地位的根本分歧,这两类政策的伦理争议可能会持续存在,政策僵局可能也会继续。